<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>NF-&amp;#x03BA;B usually has antiapotptic effects and is involved in regulation of cell proliferation and intercellular communication </plain></SENT>
<SENT sid="1" pm="."><plain>This is also true for the malignant cells in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), including the malignant stem cells </plain></SENT>
<SENT sid="2" pm="."><plain>However, both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients are <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> with regard to the effect of pharmacological NF-&amp;#x03BA;B inhibition, and the final effect will probably also depend on the pharmacological agent used for the inhibition, e.g. proteasomal inhibitiors versus specific inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>Even though initial studies suggest that NF-&amp;#x03BA;B inhibitors have antileukemic effects, their future clinical use will also depend on their toxicity profile </plain></SENT>
</text></document>